NAD+: Coenzyme Research Guide for Laboratory Use (2026)
Last updated
Introduction (research-only scope)
NAD+ (nicotinamide adenine dinucleotide) is not a peptide but a coenzyme present in every living cell, and it is one of the most researched molecules in metabolism and ageing biology. It is included in this catalog as a laboratory reagent for in-vitro work. This guide covers the biology, what the literature supports, and how our material is documented.
Research use only. The material described here is a laboratory reagent for in-vitro research by qualified professionals. It is not a medicine, supplement, cosmetic ingredient or veterinary product, is not for human or animal use, and nothing on this page is medical advice or a claim of effect in any person.
What is NAD+?
NAD+ is a dinucleotide of nicotinamide mononucleotide and adenosine monophosphate (molecular mass 663.43, CAS 53-84-9). Cells synthesise it de novo from tryptophan and by salvage from nicotinamide and its precursors. Peptra Labs supplies it as a lyophilised reagent, 500 mg per vial; because it is a small-molecule coenzyme rather than a peptide, batch documentation focuses on measured content rather than peptide purity.
How the reported mechanism works
Redox cofactor
The classical role is as an electron carrier in glycolysis, the citric acid cycle and oxidative phosphorylation, cycling between NAD+ and NADH.
Substrate for signalling enzymes
Modern interest comes from its role as a consumed substrate for sirtuins, PARPs and CD38, which links cellular NAD+ availability to gene silencing, DNA repair and immune signalling. Declining tissue NAD+ with age is a repeatedly reported observation in animal models.
What the published evidence covers
The preclinical literature is large; the 2018 Cell Metabolism review remains the standard survey of in-vivo evidence for NAD-boosting molecules. A 2025 Nature Aging review sets out where clinical translation stands and what remains unresolved, and it is worth reading precisely because it is explicit about the gaps. Note that most human studies use precursors such as nicotinamide riboside or NMN rather than NAD+ itself, so results do not transfer directly to this reagent.
How to verify a NAD+ research peptide is real and pure
Two tests answer two different questions: mass spectrometry confirms identity (expected molecular mass 663.43), HPLC quantifies purity. Our specification is at least 98%. The published report for batch GY058 reported 509.15 mg measured content (quantity test, not a purity assay) and can be checked on the testing laboratory’s own platform: third-party verification. Match the batch number printed on your vial against the lab reports archive rather than relying on a certificate image; what a valid certificate must contain is explained in how to read a certificate of analysis.
Storage and reconstitution
Store the lyophilised material sealed, dry and protected from light at 2 to 8 °C for routine laboratory use, colder for long-term archiving. After reconstitution with bacteriostatic water, keep refrigerated and use within the window your protocol defines; repeated freeze-thaw cycles degrade peptides. General handling for all our reagents is in the peptide storage protocol.
Regulatory status
NAD+ is an endogenous coenzyme and is not an authorised medicine in the European Union, the United Kingdom or the United States; some precursors are marketed as food supplements in some jurisdictions, but the reagent supplied here is neither a supplement nor a medicine. It is not named on the WADA Prohibited List. Research-grade material supplied here is not a medicine and is for in-vitro laboratory use only. The wider framework, including anti-doping status, is described in the peptide risk profile.
Why labs choose our NAD+
Batch-numbered vials, published reports where a batch has been tested, shipping from an EU warehouse with tracking (no customs inside the EU) and prices shown with VAT included. Product page: NAD+ 500 mg. Country-by-country sourcing questions are covered in the buyer guide Buy NAD+ in Europe.
References
- Rajman L, Chwalek K, Sinclair DA. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab. 2018. PubMed 29514064
- Emerging strategies, applications and challenges of targeting NAD(+) in the clinic. Nat Aging. 2025. PubMed 40926126